Cell Therapy Using Ex Vivo Reprogrammed Macrophages Enhances Antitumor Immune Responses in Melanoma

Investigators reprogrammed antitumor and proinflammatory macrophages ex vivo with HDAC6 inhibitors. Scientists administered the reprogrammed macrophages intratumorally as an adoptive cell therapy in the syngeneic SM1 murine melanoma model and patient-derived xenograft bearing NSG-SGM3 humanized mouse models.